KIMS Files Regulatory Compliance for Q3FY26 Results Showing 29% Revenue Growth
Krishna Institute of Medical Sciences demonstrated strong Q3FY26 performance with consolidated revenue growing 29.17% to Rs 9,977 million, though net profit declined 39.80%. The company approved Rs 100 crore investment in subsidiary Sarvejana Healthcare and completed regulatory compliance filing for newspaper publication of results.
*this image is generated using AI for illustrative purposes only.
Krishna Institute of Medical Sciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, demonstrating strong operational performance and strategic expansion initiatives. The healthcare services provider has also completed regulatory compliance requirements by filing necessary documentation with stock exchanges regarding newspaper publication of its financial results.
Consolidated Financial Performance
The company delivered robust consolidated financial results for Q3FY26, with revenue from operations showing substantial growth compared to the previous year.
| Metric: | Q3FY26 | Q3FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations: | Rs 9,977 million | Rs 7,724 million | +29.17% |
| Total Income: | Rs 10,029 million | Rs 7,902 million | +26.91% |
| Net Profit (Owners): | Rs 534 million | Rs 887 million | -39.80% |
| Basic EPS: | Rs 1.33 | Rs 2.22 | -40.09% |
For the nine-month period ended December 31, 2025, the company maintained strong momentum with consolidated revenue from operations reaching Rs 28,300 million compared to Rs 22,381 million in the corresponding period of the previous year, marking a growth of 26.43%.
Standalone Results Show Consistent Growth
The standalone financial performance also reflected positive trends, with the parent company showing healthy operational metrics.
| Parameter: | Q3FY26 | Q3FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | Rs 4,419 million | Rs 3,475 million | +27.17% |
| Net Profit: | Rs 725 million | Rs 765 million | -5.23% |
| Basic EPS: | Rs 1.81 | Rs 1.91 | -5.24% |
The standalone revenue growth of 27.17% in Q3FY26 demonstrates the core business strength, while the nine-month standalone revenue reached Rs 12,453 million compared to Rs 10,382 million in the previous year.
Strategic Investment in Material Subsidiary
The Board of Directors approved a significant strategic initiative involving increased investment in Sarvejana Healthcare Private Limited, the company's material subsidiary operating Sunshine Hospital.
| Investment Details: | Specifications |
|---|---|
| Investment Amount: | Up to Rs 100 crores |
| Investment Structure: | One or more tranches |
| Target Entity: | Sarvejana Healthcare Private Limited |
| Current KIMS Stake: | 75.53% |
| Subsidiary Turnover (FY25): | Rs 597.00 crores |
Sunshine Hospital, incorporated on December 3, 2008, operates as a specialized orthopedic hospital with joint replacement as its core service, supplemented by other high-end healthcare facilities including cardiology and transplant services.
Regulatory Compliance and Publication
The company has fulfilled its regulatory obligations under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results were published on February 6, 2026, in Financial Express (English) and Navatelangana (Telugu) newspapers. Company Secretary Nagajayanthi J.R. filed the compliance documentation with BSE and NSE on February 7, 2026, confirming adherence to disclosure requirements. The published results are also accessible on the company's website under investor disclosures section.
Historical Stock Returns for Krishna Institute of Medical Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.91% | -1.38% | -11.75% | -10.61% | +1.11% | +225.69% |
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
